BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idiopathic Pulmonary Fibrosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Idiopathic Pulmonary 
 Fibrosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07583589-1977@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Nintedanib (Ofev): Phase 2 readout est. (NCT07583589)
DESCRIPTION:Nintedanib (Ofev)\, phase 2\, Idiopathic Pulmonary Fibrosis.\nS
 tudy: Nintedanib With or Without Dextromethorphan in Patients With Idiopat
 hic Pulmonary Fibrosis (IPF)\nEstimated primary completion: 1 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nintedanib-ofev#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07583589
URL:https://assetmemo.bio/drug/nintedanib-ofev#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238622-10645@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:Nerandomilast (Jascayd): Phase 3 readout est. (NCT06238622)
DESCRIPTION:Nerandomilast (Jascayd)\, phase 3\, Idiopathic Pulmonary Fibros
 is.\nStudy: A Follow-up Study to Test Long-term Treatment With Nerandomila
 st in People With Pulmonary Fibrosis Who Took Part in a Previous Study Wit
 h Nerandomilast\nEstimated primary completion: 28 April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06238622
URL:https://assetmemo.bio/drug/nerandomilast-jascayd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868419-10655@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Haduvio (Nalbuphine ER): Phase 3 readout est. (NCT07868419)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 3\, Chronic Cough in Idiopathic
  Pulmonary Fibrosis.\nStudy: Idiopathic Pulmonary Fibrosis (IPF)-Related C
 hronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets
 \nEstimated primary completion: August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07868419
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07519070-1385@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20280405
DTEND;VALUE=DATE:20280406
SUMMARY:HSK44459: Phase 3 readout est. (NCT07519070)
DESCRIPTION:HSK44459\, phase 3\, Idiopathic Pulmonary Fibrosis.\nStudy: A M
 ulticenter\, Randomized\, Double-Blind\, Placebo-Controlled Phase III Stud
 y to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With
  Idiopathic Pulmonary Fibrosis\nEstimated primary completion: 5 April 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07519070
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671911-10655@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Haduvio (Nalbuphine ER): Phase 3 readout est. (NCT07671911)
DESCRIPTION:Haduvio (Nalbuphine ER)\, phase 3\, Chronic Cough in Idiopathic
  Pulmonary Fibrosis.\nStudy: Idiopathic Pulmonary Fibrosis (IPF)-Related C
 hronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets\n
 Estimated primary completion: June 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nalbuphine-er#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07671911
URL:https://assetmemo.bio/drug/nalbuphine-er#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04905693-520@assetmemo.bio
DTSTAMP:20261121T005034Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Treprostinil (Tyvaso): Phase 3 readout est. (NCT04905693)
DESCRIPTION:Treprostinil (Tyvaso)\, phase 3\, Idiopathic Pulmonary Fibrosis
 .\nStudy: Extension Study of Inhaled Treprostinil in Subjects With Fibroti
 c Lung Disease\nEstimated primary completion: December 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04905693
URL:https://assetmemo.bio/drug/treprostinil-tyvaso#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
